Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multidrug-resistant (MDR) bacterial infections.
Spero Therapeutics was founded in 2013 and went public on November 2, 2017.
Spero Therapeutics is listed on the NASDAQ Global Market with a ticker symbol of SPRO.
Spero Therapeutics is headquartered in Cambridge, MA.
You can find information about the Board of Directors and Leadership Team on our website, here.
We currently do not pay a dividend and do not offer a Dividend Reinvestment Plan.
84833T103.
You will need to open a brokerage account.
Please contact your broker if you own your shares through a broker, or if you beneficially own your shares, please contact our transfer agent.
Computershare is Spero's transfer agent.
Our independent auditor is PwC.
Spero Therapeutics is incorporated in Delaware, United States.
You can reach out to investor relations at IR@sperotherapeutics.com.
To subscribe to Spero Therapeutics’ email list, sign up here.
All SEC filings can be found and downloaded here.
Spero Therapeutics is committed to advancing novel treatment approaches for rare diseases and MDR bacterial infections. Our experienced team of experts embrace the Latin word “spero,” which means “hope.” It is our mission to bring hope to patients and families of loved ones suffering from rare diseases and serious infections.
Spero Therapeutics is pursuing collaborations with partners for expertise and funding support.
Join our life-changing mission to deliver differentiated treatments to patients suffering with rare diseases and MDR bacterial infections. We seek individuals with unique talents who share our passion.
Have a question? Reach out to us!
